IKT vs VTRS
IKT: A pre-revenue biotech company developing IKT-001, a novel therapeutic targeting pulmonary arterial hypertension, currently in Phase 3 clinical trials with no approved products or operating revenue. VTRS: A global pharmaceutical giant supplying over 1 billion patients annually with generics, branded medicines, and an expanding innovative pipeline across more than 165 countries.
Side-by-side fundamentals
| Metric | IKT | VTRS | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $2.35 | $17.64 | |
| Market cap as of 2026-08-01 | $301M | $20.5B | |
| PEG as of 2026-08-01 | n/a | 1.68 | |
| Net margin as of 2026-08-01 | -5981.3% | -2.0% | VTRS higher |
| Gross margin as of 2026-08-01 | n/a | +39.8% | |
| Operating margin as of 2026-08-01 | -6253.1% | +0.3% | VTRS higher |
| ROE as of 2026-08-01 | -57.1% | -2.0% | VTRS higher |
| ROA as of 2026-08-01 | -52.8% | -0.8% | VTRS higher |
| Debt / equity as of 2026-08-01 | 0.00 | 0.98 | IKT lower |
| Revenue growth (YoY) as of 2026-08-01 | n/a | +1.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -4.2% | |
| Dividend yield as of 2026-08-01 | n/a | +2.7% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-01 | 0.95 | 0.90 | |
| 1-year return as of 2026-07-27 close | +32.8% | +87.5% | VTRS higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.